Allianz Asset Management
NGM

Allianz Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Allianz Asset Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,070
Closed -$733K – 2466
2022
Q1 		$733K Buy
+48,070
New +$750K ﹤0.01% 1993

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Allianz Asset Management's NGM Position: Q2 2022 in Review

Allianz Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2022, closing a stake of 48,070 shares — an estimated $733K sold.

Allianz Asset Management first reported a position in NGM in Q1 2022 and held it in 1 quarter. The position peaked at $733K in Q1 2022. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

  • Allianz Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Allianz Asset Management sold 48,070 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $733K.
  • Allianz Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Allianz Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $733K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Allianz Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.